Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4029210 | Ophthalmology | 2007 | 7 Pages |
Abstract
Short-term results indicate that inhibition of vascular endothelial growth factor by intravitreal bevacizumab is associated with a decrease in retinal thickness and a reduction in angiographic leakage in type 2 IMT. Furthermore, intravitreal bevacizumab may improve VA in affected patients.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter MD, Frank G. MD, Hendrik P.N. MD, MA,